Author/Authors :
Aras, Omer Department of Radiology - Memorial Sloan Kettering Cancer Center, New York, USA , Harmsen, Stefan Molecular Imaging Program at Stanford (MIPS) - Department of Radiology - School of Medicine Stanford University, Stanford, USA , Ting, Richard Molecular Imaging Innovations Institute (MI3) - Department of Radiology - Weill Cornell Medical College, New York, USA , Sayman, Haluk B Department of Nuclear Medicine - Cerrahpasa Medical Faculty - Istanbul University-Cerrahpasa, Istanbul, Turkey
Abstract :
Targeted radionuclide therapy has emerged as a promising and potentially curative strategy for high-grade prostate cancer. However, limited data are available on efficacy, quality of life, and pretherapeutic biomarkers. Here, we highlight the case of a patient with prostate-specific membrane antigen (PSMA)-positive metastatic castrate-resistant prostate cancer who displayed complete response to 225Ac-PSMA-617 after having been resistant to standard-of-care therapy, then initially partially responsive but later resistant to subsequent immunotherapy, and resistant to successive 177Lu-PSMA-617. In addition, the patient’s baseline germline mutation likely predisposed him to more aggressive disease.
Keywords :
225Ac-PSMA , metastatic prostate cancer , radioligand therapy , genetic alterations
